B
Bernd W. Scheithauer
Researcher at Mayo Clinic
Publications - 729
Citations - 58507
Bernd W. Scheithauer is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Adenoma & Pituitary adenoma. The author has an hindex of 119, co-authored 729 publications receiving 55985 citations. Previous affiliations of Bernd W. Scheithauer include University of North Dakota & University of Michigan.
Papers
More filters
Journal ArticleDOI
Management of malignant pineal germ cell tumors with residual mature teratoma.
TL;DR: Residual pineal tumor occurring after treatment of malignant intracranial germ cell tumor with neoadjuvant therapy is likely to be mature teratoma.
Journal ArticleDOI
Clinicopathological Characteristics of Atypical Teratoid/Rhabdoid Tumor
TL;DR: Meta-analysis of 133 cases, including 15 new and 118 reported cases, confirm that atypical teratoid/rhabdoid tumor is as a clinicopathological entity and emphasizes the necessity for distinguishing this unique tumor from other pediatric central nervous system neoplasms.
Journal ArticleDOI
The 2007 WHO classification of tumors of the nervous system: controversies in surgical neuropathology.
TL;DR: N nosologic issues remain to be resolved, some a reflection of conceptual disagreement, others the result of inadequate data to permit their definitive resolution.
Journal ArticleDOI
Epithelial and pseudoepithelial differentiation in glioblastoma and gliosarcoma: a comparative morphologic and molecular genetic study.
Fausto J. Rodriguez,Bernd W. Scheithauer,Caterina Giannini,Sandra C. Bryant,Robert B. Jenkins +4 more
TL;DR: Glioblastomas exhibit a remarkable tendency toward morphologic diversity, and pseudoepithelial components (adenoid or epithelioid) or true epithelial differentiation may occur, posing a significant diagnostic challenge.
Journal ArticleDOI
Corticotroph carcinoma of the pituitary: a clinicopathological study. Report of four cases.
Thomas A. Gaffey,Bernd W. Scheithauer,Ricardo V. Lloyd,Peter C. Burger,Peter D. Robbins,Forouzandeh Fereidooni,Eva Horvath,Kalman Kovacs,Takao Kuroki,William F. Young,Thomas J. Sebo,Darren L. Riehle,Allan J. Belzberg +12 more
TL;DR: Findings support the concept that primary tumors that exhibit mitotic activity, an increased MIB-1 labeling index, and/or p53 immunoreactivity should be termed "atypical adenomas" to denote their aggressive potential and the possibility of future malignant transformation.